These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6806086)

  • 21. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites.
    Nau H; Helge H; Luck W
    J Pediatr; 1984 Apr; 104(4):627-34. PubMed ID: 6423793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
    Lewandowski C; Klug S; Nau H; Neubert D
    Arch Toxicol; 1986 Apr; 58(4):239-42. PubMed ID: 3087328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of free fatty acids on valproic acid plasma protein binding during fasting in normal humans.
    Bowdle TA; Patel IH; Levy RH; Wilensky AJ
    Eur J Clin Pharmacol; 1982 Oct; 23(4):343-7. PubMed ID: 6816619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance.
    Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
    Drug Metab Dispos; 2000 Jul; 28(7):845-56. PubMed ID: 10859159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serial free and plasma valproic acid and phenytoin monitoring and drug interactions.
    Haidukewych D; Rodin EA
    Ther Drug Monit; 1981; 3(3):303-7. PubMed ID: 6798720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding parameters of valproic acid to serum protein in healthy adults at steady state.
    Kodama Y; Koike Y; Kimoto H; Yasunaga F; Takeyama M; Teraoka I; Fujii I
    Ther Drug Monit; 1992 Feb; 14(1):55-60. PubMed ID: 1546390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should we routinely measure free plasma phenytoin concentration?
    Rimmer EM; Buss DC; Routledge PA; Richens A
    Br J Clin Pharmacol; 1984 Jan; 17(1):99-102. PubMed ID: 6419764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valproic acid has temporal variability in urinary clearance of metabolites.
    Reith DM; Andrews J; McLaughlin D
    Chronobiol Int; 2001 Jan; 18(1):123-9. PubMed ID: 11247111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of valproic acid in volunteers after a single dose study.
    Bialer M; Hussein Z; Raz I; Abramsky O; Herishanu Y; Pachys F
    Biopharm Drug Dispos; 1985; 6(1):33-42. PubMed ID: 3921078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circadian variation of Valproic acid pharmacokinetics in mice.
    Ben-Cherif W; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA
    Eur J Pharm Sci; 2013 Jul; 49(4):468-73. PubMed ID: 23707469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate.
    Della Paschoa OE; Voskuyl RA; Danhof M
    Br J Pharmacol; 1998 Dec; 125(7):1610-6. PubMed ID: 9884091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased plasma protein binding of phenytoin in patients on valproic acid.
    Dahlqvist R; Borgå O; Rane A; Walsh Z; Sjöqvist F
    Br J Clin Pharmacol; 1979 Dec; 8(6):547-52. PubMed ID: 391256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placental transfer of anticonvulsants (phenobarbital, phenytoin, valproic acid) and the elimination from neonates.
    Ishizaki T; Yokochi K; Chiba K; Tabuchi T; Wagatsuma T
    Pediatr Pharmacol (New York); 1981; 1(4):291-303. PubMed ID: 6810293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparison of two prediction methods.
    Kerrick JM; Wolff DL; Graves NM
    Ann Pharmacother; 1995 May; 29(5):470-4. PubMed ID: 7655129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unbound plasma phenytoin concentrations measured using enzyme immunoassay technique on the cobas MIRA analyser--in vivo effect of valproic acid.
    Sallustio BC; Morris RG
    Ther Drug Monit; 1992 Feb; 14(1):9-13. PubMed ID: 1546396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding parameters of phenytoin during monotherapy and polytherapy.
    Pospísil J; Perlík F
    Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):24-8. PubMed ID: 1348053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.
    Kondo T; Otani K; Hirano T; Kaneko S; Fukushima Y
    Br J Clin Pharmacol; 1990 Jan; 29(1):116-9. PubMed ID: 2105099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact.
    De Smet R; Van Kaer J; Liebich H; Lesaffer G; Verstraete A; Dhondt A; Duym P; Lameire N; Vanholder R
    Clin Chem; 2001 May; 47(5):901-9. PubMed ID: 11325895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum protein binding of valproic acid in fetus-mother pairs throughout pregnancy: correlation with oxytocin administration and albumin and free fatty acid concentrations.
    Nau H; Krauer B
    J Clin Pharmacol; 1986 Mar; 26(3):215-21. PubMed ID: 3082943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.